Coloplast expects Kerecis' rapid growth to justify the high price of the acquisition. The Icelandic company's skin-substitute products are made from minimally processed cod skins.

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat. This article is reprinted from the June issue of Medtech Insight.